D-Index & Metrics Best Publications

Michael Kneba

Kiel University
Germany

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 80 Citations 35,274 334 World Ranking 11665 National Ranking 597

Overview

What is he best known for?

The fields of study Michael Kneba is best known for:

Cancer
Chemotherapy
Gene

His Internal medicine study frequently draws connections to other fields, such as Concordance. In his articles, Michael Kneba combines various disciplines, including Oncology and Gastroenterology. Gastroenterology and Oncology are two areas of study in which he engages in interdisciplinary research. His Genetics study frequently draws connections to other fields, such as Gene rearrangement. He performs integrative Leukemia and Immunophenotyping research in his work. In his research, he performs multidisciplinary study on Immunophenotyping and Leukemia. His study deals with a combination of Gene and Germline mutation. Immunology and Antibody are two areas of study in which he engages in interdisciplinary work. In his research, Michael Kneba undertakes multidisciplinary study on Antibody and Rituximab.

His most cited work include:

Pan-cancer analysis of whole genomes (1513 citations)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions (1184 citations)
Mutations driving CLL and their evolution in progression and relapse (766 citations)

What are the main themes of his work throughout his whole career to date

His research links Cancer with Internal medicine. Much of his study explores Cancer relationship to Internal medicine. He performs multidisciplinary study in the fields of Oncology and Gastroenterology via his papers. With his scientific publications, his incorporates both Gastroenterology and Oncology. He conducts interdisciplinary study in the fields of Leukemia and Chronic lymphocytic leukemia through his research. In his works, Michael Kneba undertakes multidisciplinary study on Chronic lymphocytic leukemia and Leukemia. His study ties his expertise on Immunology together with the subject of Minimal residual disease. His work on Minimal residual disease expands to the thematically related Immunology. In his works, he performs multidisciplinary study on Genetics and Cancer research.

Michael Kneba most often published in these fields:

Internal medicine (72.22%)
Oncology (53.70%)
Leukemia (44.44%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

J J M van Dongen;A W Langerak;M Brüggemann;P A S Evans.
Leukemia (2003)

2657 Citations

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Michael Hallek;K. Fischer;Gunter Fingerle-Rowson;A.M. Fink.
The Lancet (2010)

2214 Citations

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Wolfgang Hiddemann;Michael Kneba;Martin Dreyling;Norbert Schmitz.
Blood (2005)

1865 Citations

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Valentin Goede;Kirsten Fischer;Raymonde Busch;Anja Engelke.
The New England Journal of Medicine (2014)

1631 Citations

Pan-cancer analysis of whole genomes

Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart.
(2020)

1275 Citations

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.

Salah-Eddin Al-Batran;Nils Homann;Claudia Pauligk;Thorsten O Goetze.
The Lancet (2019)

1191 Citations

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp;Peter Kufer;Nicola Gökbuget;Mariele Goebeler.
Journal of Clinical Oncology (2011)

1164 Citations

Mutations driving CLL and their evolution in progression and relapse.

Dan A. Landau;Eugen Tausch;Amaro N. Taylor-Weiner;Chip Stewart.
Nature (2015)

908 Citations

ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology

J. Arends;G. Bodoky;F. Bozzetti;K.C. Fearon.
Clinical Nutrition (2006)

898 Citations

The landscape of genomic alterations across childhood cancers

Susanne N. Gröbner;Barbara C. Worst;Joachim Weischenfeldt;Joachim Weischenfeldt;Ivo Buchhalter.
Nature (2018)

840 Citations

If you think any of the details on this page are incorrect, let us know.

Michael Kneba

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Overview

What is he best known for?

The fields of study Michael Kneba is best known for:

His most cited work include:

What are the main themes of his work throughout his whole career to date

Michael Kneba most often published in these fields:

Best Publications

Report an issue

Frequent Co-Authors

Best Scientists Citing Michael Kneba

Trending Scientists